About Us

Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing the world’s 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products including prescription generic, branded generic, brand-name drugs and over-the-counter remedies. We market our products in more than 165 countries and territories. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world.

Our mission is grounded in the belief that every person matters and should have the opportunity to live the healthiest life possible. We've built our business model consistent with this belief. Through it, we are impacting people around the world with each passing year.

Providing universal access to medicine is the core purpose of our model, pictured below.

To provide access, we must be able to satisfy the needs of an incredibly diversified global marketplace whose economic and political systems, approaches to delivering and paying for healthcare, languages and traditions, and customer and patient requirements vary by location and over time.

Mylan Business Model


Explore nearly 60 years of unconventional success.

  1. Mylan Founded
    Mylan Founders

    Day 1

    First known as Milan, the company starts doing business in White Sulphur Springs, West Virginia. U.S. Army buddies, Milan "Mike" Puskar and Don Panoz flip a coin to see who will name the business and who will be the company’s first president. They start distributing products to doctors and pharmacists from an old Pontiac Bonneville.
    Mylan Founders
  2. 0

    Moves to Morgantown

    We move to Morgantown, West Virginia in 1965 and begin manufacturing various over-the-counter products the next year. Success leads to a decision to switch production to generic pharmaceuticals.

  3. Mylan FDA approval
    Mylan Penicillin G

    Our First Medicine

    After receiving approval from the U.S. Food and Drug Administration to manufacture our first medicine, Penicillin G, we broaden our product line to include other generic antibiotics as well as analgesics, antihistamines, diuretics and tranquilizers. We market these to large drug companies, drug store chains and mail-order drug providers, all for resale under the customers’ own labels.

    Mylan Penicillin G
  4. 0

    New Partner, New Look

    Parke-Davis is the first major pharmaceutical company to purchase and privately label Milan products. We also introduce a new logo—the letter “M” formed by three test tubes suggests scientific leadership and teamwork.

  5. 0

    From Milan to Mylan

    We change the spelling of Mylan to stand out at the bottom of the list of stocks that begin with the letter "M."

  6. Mylan goes public

    Going Public

    To fuel expansion, Mylan goes public.

    By the end of the 1970s, we produce five of the 10 most prescribed generic medicines—all five are antibiotics.
  7. 0
    1976: New Leadership

    New Leadership

    Mike Puskar, who had left the company, returns as president. He and chairman and CEO Roy McKnight lead Mylan through a period of unprecedented growth.

    1976: New Leadership
  8. Generic Pharmaceutical Industry Association
    Mike Puskar

    GPIA and Hatch-Waxman

    Mike Puskar helps establish the Generic Pharmaceutical Industry Association, GPIA, to give the industry a voice. During the next few years, GPIA lobbies for the Hatch-Waxman Act, which passes in 1984.

    Mike Puskar
  9. First-to-Market
    1984: First to Market

    First to Market

    Our first branded product approval, for MAXZIDE® TABLETS (triamterene and hydrocholorothiazide tablets, US), is a first for a generics company.

    1984: First to Market
  10. 0

    Doing What’s Right, Not What’s Easy

    We see irregularities in how the FDA acts on abbreviated new drug applications. Our investigation helps expose fraudulent practices and corruption in the industry. This results in reform of the FDA’s review procedures for generic drugs and new precautions to help ensure consumer safety.

  11. Bertek & UDL Labs
    Bertek & UDL Labs


    The market is becoming increasingly competitive as demand for high quality, affordable medication rises.

    • In 1993, we acquire Bertek Inc., an innovator of transdermal medicine systems. Bertek is later renamed Mylan Technologies Inc., or MTI
    • In 1996, Mylan adds unit dose packaging with the acquisition of UDL, the largest pharmaceutical unit dose packaging company in the U.S.
    • At the same time, generic use rises to about 47%, and we continue to capture market share while discontinuing private labeling and growing our own “Mylan” label
    Bertek & UDL Labs
  12. 0

    New CEO

    Mike Puskar becomes chairman and CEO.

  13. Biggest pharma companies

    Another First

    We become the most-dispensed line of brand and generic pharmaceuticals in the U.S.

  14. Mylan 2002 revenue
    Mylan Packaging

    Growing Into the 21st Century

    Soon after entering our fifth decade, we post revenue of $1 billion.

    Mylan Packaging
  15. 0
    Robert J. Coury

    Robert J. Coury

    Robert J. Coury is elected to the board of directors and becomes vice chairman and CEO.

    Robert J. Coury
  16. 0

    Added to S&P 500

    In 2004, Mylan was added to the S&P 500 and shipped 11 billion doses, more than any other pharmaceutical company.

  17. Generic vs. Brand

    Organic Growth

    In the U.S., the Medicare Prescription Drug, Improvement and Modernization Act and an aging Medicare population fuel generic utilization, which reaches 78% by decade’s end. We are ready, having put in place a plan to expand through organic growth and acquisitions from a mid-size company into a global leader.

  18. 0

    Setting New Standards in Healthcare

    Executive Heather Bresch testifies before the U.S. Senate’s Special Committee on Aging regarding issues that put billions of dollars of consumer healthcare savings at risk.

  19. Mylan Global
    Matrix Labs

    Going Global

    We become a global company by acquiring a controlling interest in Matrix Laboratories and by purchasing Merck KGaA’s generics business.

    • In addition to being a supplier of active pharmaceutical ingredients (API), Matrix has low-cost manufacturing facilities in India and China and marketing capabilities in Western Europe and Africa. Matrix gives us unprecedented control over our supply chain and expands our dosage forms and therapeutic categories. This includes the addition of antiretroviral medicines for people living with HIV/AIDS
    • Merck KGaA’s generic business sells products in more than 90 countries. Combining forces provides massive global scale, expands our product portfolio and provides entry into new commercial markets
    • With the acquisition of Merck KGaA generic business, we acquire the rights to EpiPen® (epinephrine injection, USP) Auto-Injector, the world's No. 1 dispensed epinephrine auto-injector*
    • *IMS data, 1987-2012
    Matrix Labs
  20. Mylan 2008 revenue

    Continued Growth

    We post revenue of $5 billion.

  21. 0

    Global Leadership

    • Mike Puskar retires and Robert J. Coury is named chairman of the board.
    • We launch next-generation EpiPen® (epinephrine injection, USP) Auto-Injector.
    • Our first global product, LANSOPRAZOLE (lansoprazole capsule, delayed release pellets), launches.
    • Lopinavir/Ritonavir, an innovative heat-stable ARV treatment, is created for use in certain countries where refrigeration isn't readily available.
    • Robert J. Coury and former President Bill Clinton announce an agreement for better, more affordable treatment for HIV/AIDS patients in the developing world.
    • Mylan and Biocon partner to enter the global generics biologics market.
  22. 0

    Bioniche Pharma

    Our acquisition of Bioniche Pharma expands our injectable portfolio with products for use in orthopaedics, rheumatology, urology and dermatology.

  23. 0
    Mylan book

    Our First 50 Years

    • Mylan celebrates 50 years of unconventional success.
    • We acquire Pfizer’s respiratory delivery platform.
    Mylan book
  24. FDASIA

    Championing National Policy

    Mylan, led by Heather Bresch, champions the Food and Drug Administration Safety and Innovation Act (FDASIA), which holds both foreign and domestic manufacturers to one global quality standard. The Act includes the Generic Drug User Fee Act (GDUFA). Together, FDASIA and GDUFA aim to speed up access to safe and effective generic medicines while providing more visibility into how medicines and their ingredients are manufactured and shipped around the world.

  25. 0
    Mylan Executives

    Expanding Leadership

    We introduce a new and expanded management structure to help fuel our continued growth and success. Robert J. Coury transitions into the role of executive chairman of the board. Heather Bresch is promoted to CEO; Rajiv Malik is promoted to president.

    Mylan Executives
  26. 0
    Mylan India

    Unprecedented Growth

    • We launch commercial operations in India and team up with Pfizer in Japan
    • Mylan is selected as a supplier to India’s National AIDS Control Organization and is named the leading antiretroviral supplier to the South African National Department of Health
    Mylan India
  27. 0

    Ongoing Global Leadership

  28. 0

    Strengthening our Partnership

    Launched Hertraz®, first Trastuzumab biosimilar, in India

    Expanded our partnership with Gilead in India and beyond for Hepatitis C treatment
  29. 0

    Better Health for a Better World

    Mylan acquires Abbott's non-U.S. developed markets specialty and branded generics business

    Acquired certain businesses from Famy Care to become a global women’s healthcare leader
  30. 0

    Growing with Purpose

    Acquired topicals-focused specialty and generics business from Renaissance

    Acquired Meda, a leading international specialty pharmaceutical company

    Robert J. Coury becomes Chairman, Mylan Board of Directors
  31. 0

    Strong Operating Performance

    Achieved $10B in annual revenue for the first time.

Our Mission

Mylan's Mission

Our Values

Mother and daughter laughing
We are unconventional, visionary and bold. We “connect the dots” others overlook. We see possibilities and bring them to life. We love to challenge the status quo and introduce new and better ways to help people everywhere enjoy a higher quality of life. Having the courage to be a force for constructive change is in our DNA.

We see the opportunity to innovate in every challenge

Doing what's right is sacred to us. We behave responsibly, even when nobody's looking. We set high standards from which we never back down. This uncompromising ethical stance helps to keep our products pure, our workers safe and the environment clean.

Watch our Integrity at work

Dependable. Reliable. Call it what you will, we've made it a habit. We strive to be there through thick and thin, rain or shine, delivering on every promise, every time. That's why people around the corner and across the world count on Mylan.

Seven billion people rely on us

We understand that "it's not about us"—it's about helping others—and we believe there's no situation we can't handle. We would do whatever it takes, work ‘round the clock, cross any river and spare no effort—all to meet someone’s need. We wrap our high quality products in high quality service.

Creating access to HIV/AIDS medications and physicians

Together, we can run faster, reach higher and achieve more than any one of us can alone. We relish opportunities to collaborate because it’s invigorating, enlightening and powerful. When we join forces and plow through boundaries, we move mountains.

Meet our leadership team

1961: Year founded in White Sulphur Springs, West Virginia, U.S.
~7 billion: People we work to provide with access to high quality medicine
>165: Countries and territories in which our products are sold
>7,500: Separate products currently being marketed
>75 billion: Oral solid dose capacity
~35,000: Workforce

Fact Sheet

Mylan Fact Sheet